Jillian Marie Hagel - 25 Jan 2023 Form 4 Insider Report for Enveric Biosciences, Inc. (ENVB)

Reporting relationship: Vice President of Innovation
Issuer ticker: ENVB
Reported as of: 25 Jan 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 Jan 2023, 16:05:31 UTC
Prior SEC filing: 25 Jan 2023
Source filing: View source filing
Reporting owner signature: /s/ Jillian Marie Hagel

Key filing fact

Jillian Marie Hagel filed Form 4 for Enveric Biosciences, Inc. (ENVB) on 27 Jan 2023.

Key facts

This page summarizes Jillian Marie Hagel's Form 4 filing for Enveric Biosciences, Inc. (ENVB).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 27 Jan 2023, 16:05.

Change

Previous filing in this sequence was filed on 25 Jan 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ENVB transaction

Common Stock

Award

Transaction value: $0
Shares: +12,000
Change %: +50%
Price: $0.000000
Shares after: 35,802
Date: 25 Jan 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. The RSUs vest in four equal annual installments, with the first installment vesting upon the one year anniversary of the date of issuance.